Apremilast for psoriatic arthritis rejected by NICE

NICE had rejected the NHS use of apremilast (Otezla) alone or in combination for the treatment of active psoriatic arthritis when DMARDs are unsuitable.

NICE concluded that apremilast is clinically effective compared with no other treatment. However, when compared with TNF-alpha inhibitors, apremilast was the least clinically effective for treating psoriatic arthritis. Although some costs were saved by the use of apremilast, NICE concluded they were not sufficient to justify the health losses.

Further information
NICE technology appraisal TA372

Professor Carole Longson, Director of the Health Technology Evaluation Centre at NICE, explained  "there was not enough robust evidence demonstrating that apremilast slows progression of the disease compared to TNF-alpha inhibitors."

This follows a previous rejection by NICE, for the use of apremilast in moderate to severe plaque psoriasis.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...